Abstract: A guided bone regeneration material is disclosed. The guided bone regeneration material includes biodegradable fibers produced by an electrospinning method. The biodegradable fibers produced by the method include a silicon-releasing calcium carbonate and a biodegradable polymer. The silicon-releasing calcium carbonate is a composite of siloxane and calcium carbonate of vaterite phase. The biodegradable fibers may be coated with apatite. When the guided bone regeneration material is immersed in a neutral aqueous solution, silicon species ions are eluted from the calcium carbonate. The guided bone regeneration material excels in bone reconstruction ability.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
October 27, 2020
Assignees:
NATIONAL UNIVERSITY CORPORATION NAGOYA INSTITUTE OF TECHNOLOGY, ORTHOREBIRTH CO., LTD., YAMAHACHI DENTAL MFG., CO., YABASHI INDUSTRIES, CO., LTD.
Abstract: This invention generally refers to the process to obtain a compound and a standard pharmaceutical product from one or more parts of plants of the Stachytarpheta (Verbenaceae family) species, as well as roots, stems, barks, and leaves of plants in the form of extracts or enriched fractions, or pure isolated compounds or compounds obtained from synthesis, used alone or mixed with other natural or synthetic products, in different ratios, in order to integrate pharmaceutical compositions to be used by appropriate routes (topic or oral), particularly in the form of tablets, capsules, dyes, emulsions, W/O and O/W (creams and gels), liposomes, microcapsules, nanoparticles, aerosols, ointments, and the like, as well as formulations for slow-release implants, used to treat vitiligo.
Abstract: Provided herein are topical formulations containing copper ions and methods of treating inflammatory, microbial, and arthritic conditions in various areas of the body using such formulations. Methods of treating osteoarthritis using topical copper ion treatments are provided. Methods of treating and preventing microbial infections using copper ion treatments are further provided, including methods of preventing biofilm. A topical treatment in its basic form comprises a biocompatible copper ion solution or suspension obtained by leaching of the copper ions from copper metal. The copper ion solution or suspension is combined with various carriers to form the copper ion treatment including creams, gels, lotions, foams, pastes, tampons, solutions, suppositories, body wipes, wound dressings, skin patches, and suture material. Methods of making the copper ion solution or suspension from solid copper metal in a biocompatible solution are also provided.
Abstract: This invention generally refers to the process to obtain a compound and a standard pharmaceutical product from one or more parts of plants of the Stachytarpheta (Verbenaceae family) species, as well as roots, stems, barks, and leaves of plants in the form of extracts or enriched fractions, or pure isolated compounds or compounds obtained from synthesis, used alone or mixed with other natural or synthetic products, in different ratios, in order to integrate pharmaceutical compositions to be used by appropriate routes (topic or oral), particularly in the form of tablets, capsules, dyes, emulsions, W/O and O/W (creams and gels), liposomes, microcapsules, nanoparticles, aerosols, ointments, and the like, as well as formulations for slow-release implants, used to treat vitiligo.
Abstract: The present invention relates to a transmucosal administration system to administer quinones, benzoquinones, and especially 1,4-benzoquinones, via the oromucosal route.
Type:
Grant
Filed:
January 20, 2012
Date of Patent:
October 20, 2020
Assignees:
LTS Lohmann Therapie-System AG, Santhera Pharmaceuticals (Schweitz) AG
Inventors:
Markus Krumme, Keith Jensen, Judith Dubach-Powell, Rudolf Hausmann
Abstract: Pharmaceutical formulations for co-administering estradiol and progesterone are provided herein. In some embodiments, the formulation comprises solubilized estradiol, suspended progesterone, and a medium chain (C6-C12) oil.
Type:
Grant
Filed:
October 10, 2014
Date of Patent:
October 20, 2020
Assignee:
TherapeuticsMD, Inc.
Inventors:
Peter H. R. Persicaner, Brian A. Bernick, Julia M. Amadio
Abstract: A stable flowable aqueous composition comprising at least two component surfactants, each component surfactant having a maximum solubility in water at which a saturated solution forms, wherein the total concentration of all surfactants present in the composition is greater than would be obtained by combining equivalent amounts of saturated solutions of the component surfactants; wherein at least one component surfactant includes a compound of formula (I): wherein R1 represents a C4-36 alkyl group; each of R2, R3, R4 and R5 independently represents a hydrogen atom or a C1-4 alkyl group and wherein at least one of R2, R3, R4 and R5 is not hydrogen and M? represents a cation.
Abstract: According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.
Type:
Grant
Filed:
October 22, 2014
Date of Patent:
October 20, 2020
Assignee:
TherapeuticsMD, Inc.
Inventors:
Brian A. Bernick, Julia M. Amadio, Peter H. R. Persicaner
Abstract: A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-?-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.
Type:
Grant
Filed:
May 21, 2018
Date of Patent:
October 13, 2020
Assignee:
REDWOOD PHARMA AB
Inventors:
Clive H. Reading, Thomas Rowe, Mario G. Fsadni, Richard Coulon
Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.
Type:
Grant
Filed:
March 17, 2017
Date of Patent:
September 15, 2020
Assignee:
MannKind Corporation
Inventors:
Marshall L. Grant, Grayson W. Stowell, Paul Menkin, John J. Freeman, Jr.
Abstract: A water-insoluble composition, solid in appearance at a temperature of less than or equal to 20° C., comprising, for 100% of the mass of same: —X1% by mass of at least one lipophilic surfactant having a value HLB, H1, greater than or equal to 1 and less than 10; —X2% by mass of at least one hydrophilic surfactant having a value HLB, H2, greater than or equal to 10 and less than or equal to 20; characterised by the fact that the HLB of same=X1.H1+X2.H2, X1 and X2 varying from 2 to 60, and characterised in that it is free of acrylic polymer and/or of acetate succinate.
Type:
Grant
Filed:
December 7, 2015
Date of Patent:
September 15, 2020
Assignee:
SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC
Abstract: The present invention relates generally to agents and devices for promoting hemostasis and tissue sealing and, more particularly, to hemostatic pads comprising bioabsorbable scaffolds that can deliver lyophilized hemostasis promoting proteins, such as fibrinogen and thrombin, to a wound site or injured organ or tissue.
Type:
Grant
Filed:
July 9, 2013
Date of Patent:
September 8, 2020
Assignee:
Ethicon, Inc.
Inventors:
Randolph W. Hubbell, James Eckhardt, Jerome Riebman, Yufu Li, Michael Elser
Abstract: A galenical form for the administration transmucously of at least one active ingredient, characterized in that the active ingredient is in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 20% by mass of alcohol so as to allow rapid absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. Uses of the galenical form are also disclosed.
Abstract: Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.
Type:
Grant
Filed:
June 18, 2018
Date of Patent:
September 1, 2020
Assignee:
EKR Therapeutics, Inc.
Inventors:
Michelle Renee Duncan, Supriya Gupta, David Hartley Haas, Norma V. Nenonene, Camellia Zamiri
Abstract: A stretchable laminated sheet with hydrophilic properties, which particularly has an excellent feeling and stability in wearing and is capable of efficiently enhancing the effect and efficacy brought about by a liquid component on a skin or other object, when the stretchable laminated sheet is impregnated with the liquid component and wet and then used on the skin or other object.
Abstract: The present invention relates to compositions comprising a colloidal dispersion and an Agent of Interest (“AOI”), wherein the colloidal dispersion comprises deformable colloidal particles and wherein the AOI is not associated with the deformable colloidal particles. The present invention also provides kits and transdermal drug release devices comprising the compositions of the present invention, and the use of these compositions in medicine, skin care and cosmetics.
Abstract: The present invention includes methods and compositions for ameliorating symptoms or treating one or more adverse reactions triggered by infectious diseases or disease conditions that trigger a widespread release of cytokines in a subject comprising the steps of: identifying the subject in need of amelioration of symptoms or treatment of the infectious diseases or disease conditions that trigger a widespread release of cytokines; and administering one or more pharmaceutical compositions comprising a therapeutically effective amount of a curcumin extract, curcuminoids or synthetic curcumin (S-curcumin) and derivatives thereof, or empty liposomes, dissolved or dispersed in a suitable aqueous or non-aqueous medium sufficient to reduce the level of cytokines in the host.
Type:
Grant
Filed:
December 30, 2015
Date of Patent:
August 11, 2020
Assignees:
Signpath Pharma, Inc., Avanti Polar Lipids, Inc.
Inventors:
Peter P. Sordillo, Lawrence Helson, Stephen W. Burgess, Walter A. Shaw
Abstract: A cellulose-containing article for treating an area of skin, wherein the article—comprises BNC in an amount of at least 1% by weight and at most 15% by weight, —comprises fluid in an amount of at least 85% by weight and at most 99% by weight, —has an average thickness of at least 0.5 mm and at most 8 mm, wherein the BNC is of microbial origin.
Abstract: The present invention relates to a transmucosal administration system to administer quinones, benzoquinones, and especially 1,4-benzoquinones, via the oromucosal route.
Type:
Grant
Filed:
January 17, 2013
Date of Patent:
July 21, 2020
Assignee:
LTS Lohmann Therapie-Systeme AG
Inventors:
Markus Krumme, Keith Jensen, Judith Dubach-Powell, Rudolf Hausmann
Abstract: The present invention relates to a granular composition for oral suspension characterized by the presence of an insoluble resin and a silica gel.